Regulatory news
Agency actions, classification changes, enforcement letters and scheduling decisions across the EU, EEA, UK and US. Sourced to the primary regulator.
Browse other coverage
Latest from the blog
Nerve risks after weight loss drugs
A 2026 review links rare peripheral nerve problems with rapid weight loss during semaglutide or tirzepatide treatment.
Tirzepatide Injection Route Error
A single tirzepatide case report links accidental intradermal injection with increased adverse events, but cannot measure the risk.
Adolescent GLP 1s: The Muscle Gap
A new perspective uses semaglutide trial data to ask how adolescent GLP 1 care should track muscle, bone, and physical function.
Atypical anorexia after weight loss
A case report links severe restriction after sleeve gastrectomy, semaglutide, and tirzepatide with atypical anorexia nervosa.
Digital tirzepatide care study
A UK study of 8,127 women reported six-month outcomes from a structured digital programme where 99.8% started tirzepatide.
What Exit Interviews Add to GLP-1 Trials
A study from ACHIEVE-3 shows what exit interviews can add to oral GLP-1 trial results, and what they cannot answer.